Share on StockTwits

Barclays increased their target price on shares of LifePoint Hospitals (NASDAQ:LPNT) from $52.00 to $56.00 in a research note issued on Tuesday, Stock Ratings Network reports. Barclays’ price target indicates a potential upside of 4.48% from the company’s current price.

Shares of LifePoint Hospitals (NASDAQ:LPNT) opened at 53.60 on Tuesday. LifePoint Hospitals has a one year low of $42.12 and a one year high of $56.77. The stock has a 50-day moving average of $53.62 and a 200-day moving average of $49.94. The company has a market cap of $2.482 billion and a price-to-earnings ratio of 19.90.

LifePoint Hospitals (NASDAQ:LPNT) last announced its earnings results on Friday, February 14th. The company reported $0.75 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.80 by $0.05. The company had revenue of $952.60 million for the quarter, compared to the consensus estimate of $952.10 million. During the same quarter last year, the company posted $0.77 earnings per share. LifePoint Hospitals’s revenue was up 10.1% compared to the same quarter last year. Analysts expect that LifePoint Hospitals will post $3.01 EPS for the current fiscal year.

A number of other firms have also recently commented on LPNT. Analysts at Ned Davis Research downgraded shares of LifePoint Hospitals from a “buy” rating to a “neutral” rating in a research note on Monday, February 10th. Separately, analysts at CRT Capital upgraded shares of LifePoint Hospitals from a “fair value” rating to a “buy” rating in a research note on Monday, February 3rd. They now have a $60.00 price target on the stock. Ten analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $52.20.

LifePoint Hospitals, Inc (NASDAQ:LPNT), through its subsidiaries, operates general acute care hospitals in non-urban communities in the United States.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.